Related Experiment Video
Updated: Jan 14, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.1K
Updated 2025 French guidelines for renal cell carcinoma
Pierre Bigot1, Zine-Eddine Khene2, Romain Boissier3
1Comité de cancérologie de l'Association française d'urologie, groupe rein, Maison de l'urologie, 11, rue Viète, 75017 Paris, France; Department of Urology, Angers University Hospital, Angers, France.
The French Journal of Urology
|October 18, 2025
Summary
The 2025 French guidelines for localized renal cell carcinoma emphasize renal biopsy and active surveillance for small masses. New treatments and biomarkers are highlighted, alongside centralization of surgery and updated recurrence management strategies.
Area of Science:
- Urology
- Oncology
- Nephrology
Background:
- The 2025 update of French guidelines for localized renal cell carcinoma (RCC) addresses key advancements.
- Current practices are evolving with new diagnostic and therapeutic strategies.
Purpose of the Study:
- To summarize major advances in localized renal cell carcinoma management.
- To provide updated recommendations for diagnosis, treatment, and surveillance.
Main Methods:
- Review of recent evidence and expert consensus on localized renal cell carcinoma.
- Integration of new diagnostic tools, therapeutic options, and organizational principles.
Main Results:
- Renal biopsy is crucial for guiding treatment and reducing overtreatment; a "biopsy-all" strategy is supported.
- Active surveillance is effective for small renal masses, including selected complex cystic lesions.
- Stereotactic body radiotherapy is a viable option for medically inoperable patients.
- Belzutifan shows promise in von Hippel-Lindau disease-associated RCC.
- Centralization of renal cancer surgery in high-volume centers is recommended.
- Novel biomarkers (KIM-1, GAGs, ctDNA) show potential for surveillance and personalized treatment.
- Recurrence management strategies are refined based on timing after adjuvant therapy (pembrolizumab).
Conclusions:
- The updated guidelines reflect significant progress in localized renal cell carcinoma care.
- Emphasis is placed on personalized treatment, risk stratification, and multidisciplinary decision-making.
- Adoption of these advances aims to optimize oncological outcomes and patient management.
Related Concept Videos
01:06Renal Drug Clearance: Overview
663
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
663
01:11Renal Failure: Dose Adjustments
434
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
434
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
188
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
188
01:15Renal Drug Excretion: Overview
646
As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
646
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
207
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
207
01:28Chronic Kidney Disease III: Interprofessional Care
335
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
335